MDRNA Gets Research Deal With Pfizer

Xconomy Seattle — 

MDRNA (NASDAQ: MRNA), the Bothell, WA-based developer of RNA interference therapies, said today it has formed a research agreement with Pfizer. MDRNA will be responsible for taking oligonucleotides from Pfizer, and formulating them in amino acid packages that MDRNA has developed for RNA interference. The smaller company will also be asked to design and synthesize RNAi drugs against targets chosen by Pfizer. Financial terms of the deal weren’t disclosed.